Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for First Wave BioPharma, Inc. (FWBI : NSDQ)
 
 • Company Description   
First Wave BioPharma Inc. is a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal diseases. First Wave BioPharma Inc., formerly known as AzurRx BioPharma Inc., is based in BOCA RATON, Fla.

Number of Employees: 17

 
 • Price / Volume Information   
Yesterday's Closing Price: $0.36 Daily Weekly Monthly
20 Day Moving Average: 445,156 shares
Shares Outstanding: 16.70 (millions)
Market Capitalization: $6.06 (millions)
Beta: 1.78
52 Week High: $9.70
52 Week Low: $0.28
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -45.03% -39.81%
12 Week -71.21% -67.64%
Year To Date -74.89% -69.33%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
777 YAMATO ROAD SUITE 502
-
BOCA RATON,FL 33431
USA
ph: 561-589-7020
fax: -
investors@azurrx.com http://www.firstwavebio.com
 
 • General Corporate Information   
Officers
James Sapirstein - President; Chief Executive Officer; Chairman
Sarah Romano - Chief Financial Officer
Edward J. Borkowski - Director
Charles J. Casamento - Director
Terry Coelho - Director

Peer Information
- (-)
- (-)
- (-)
- (-)
- (-)
- (-)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 33749P101
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 09/01/21
Next Expected EPS Date: 05/23/22
Share - Related Items
Shares Outstanding: 16.70
Most Recent Split Date: 9.00 (0.10:1)
Beta: 1.78
Market Capitalization: $6.06 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.32 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-1.34 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 2.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 05/23/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: -
Price/Cash Flow: -
Price / Sales: -
EPS Growth
vs. Year Ago Period: 30.43%
vs. Previous Quarter: -104.37%
Sales Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -%
ROE
03/31/22 - -
12/31/21 - -3,522.67
09/30/21 - -2,190.26
ROA
03/31/22 - -
12/31/21 - -418.32
09/30/21 - -453.64
Current Ratio
03/31/22 - -
12/31/21 - 0.77
09/30/21 - 0.39
Quick Ratio
03/31/22 - -
12/31/21 - 0.77
09/30/21 - 0.39
Operating Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Net Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Pre-Tax Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Book Value
03/31/22 - -
12/31/21 - -0.53
09/30/21 - -0.63
Inventory Turnover
03/31/22 - -
12/31/21 - -
09/30/21 - -
Debt-to-Equity
03/31/22 - -
12/31/21 - -
09/30/21 - -
Debt-to-Capital
03/31/22 - -
12/31/21 - -
09/30/21 - -
 

Powered by Zacks Investment Research ©